Accordingly, the median OS was 1.64 months (95% CI = 0.46–8.91 months) for pMUT-tWT and 32.45 months (95% CI = 7.66–32.45 months) for patients with KRAS mutations in tumor tissue only. The gene discussed is KRAS; the disease is neoplasm.